RENO-60 Drug Patent Profile

Which patents cover Reno-60, and what generic alternatives are available?

Reno-60 is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in RENO-60 is diatrizoate meglumine. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the diatrizoate meglumine profile page.

Summary for RENO-60

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for RENO-60

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	RENO-60	diatrizoate meglumine	INJECTABLE;INJECTION	010040-016	Approved Prior to Jan 1, 1982		DISCN	No	No

RENO-60 Market Analysis and Financial Projection

Last updated: April 29, 2026

Investment Scenario and Fundamentals Analysis for RENO-60

No patent, regulatory, clinical, product, or corporate-identification details for “RENO-60” are provided. Without those inputs, a complete and accurate fundamentals or investment scenario analysis cannot be produced.

What business and IP facts can be verified for RENO-60?

None are available in the request. A fundamentals analysis for a drug requires at minimum: the active pharmaceutical ingredient, dosage form and strength mapping, sponsor/manufacturer, jurisdictional approvals or filings, mechanism of action, and the patent landscape (composition-of-matter, formulation, method-of-use, and key jurisdictional expiries). Those facts are not supplied.

What regulatory milestones define revenue timing?

None are provided. A credible investment scenario requires approval status by market (e.g., FDA NDA/BLA, EMA marketing authorization, local approvals), filing dates, label scope, exclusivity terms (including data and market exclusivity), and launch history. The request contains none of these.

What clinical evidence supports the valuation case?

None are provided. A fundamentals review requires efficacy endpoints, safety profile, pivotal trial identifiers, comparator context, and response durability. The request contains none.

What pricing and reimbursement conditions govern commercial upside?

None are provided. A revenue model requires at least: target indication, expected patient population, WAC list price or contract pricing references, reimbursement coverage, expected uptake curve, and competitive pricing constraints. The request contains none.

What are the key competitive and substitution risks?

None are provided. A defensible competitive assessment requires competitor mapping by mechanism, label overlap, generics/biosimilars presence, and relevant patent expiries or design-around risks. The request contains none.

What would an investor underwriting checklist look like for RENO-60?

Not computable from the provided information. Any attempt to fill gaps would produce non-verifiable claims.

---

Key Takeaways

• A complete and accurate investment fundamentals analysis for RENO-60 is not possible because no drug identity, approvals, clinical data, sponsor details, or patent/regulatory facts are supplied.
• The minimum building blocks for: IP expiry timing, regulatory exclusivity, clinical value proposition, competitive landscape, and commercial economics are missing.

FAQs

1. What is RENO-60?
   The request provides no identifying information (active ingredient, dosage form, indication, sponsor, or approval status).

2. Is RENO-60 approved in the US or EU?
   Approval status is not provided, so it cannot be validated.

3. What patents protect RENO-60 and when do they expire?
   No patent or jurisdictional expiry information is provided.

4. What clinical trials support RENO-60’s indication claims?
   No trial data, endpoints, or publications are provided.

5. What are the commercial revenue drivers for RENO-60?
   No market, pricing, reimbursement, patient population, or launch information is provided.

---

References

No sources are provided or citable from the given request.